Comments on: Investigational Subcutaneous Formulation of Vedolizumab Meets Primary Endpoint in Achieving Clinical Remission at Week 52 in Patients with Moderately to Severely Active Crohn’s Disease

Comments on: Investigational Subcutaneous Formulation of Vedolizumab Meets Primary Endpoint in Achieving Clinical Remission at Week 52 in Patients with Moderately to Severely Active Crohn’s Disease https://www.novumpr.nl/2019/07/22/investigational-subcutaneous-formulation-of-vedolizumab-meets-primary-endpoint-in-achieving-clinical-remission-at-week-52-in-patients-with-moderately-to-severely-active-crohns-disease/?utm_source=rss&utm_medium=rss&utm_campaign=investigational-subcutaneous-formulation-of-vedolizumab-meets-primary-endpoint-in-achieving-clinical-remission-at-week-52-in-patients-with-moderately-to-severely-active-crohns-disease NovumPR press releases Mon, 22 Jul 2019 05:41:14 +0000 hourly 1 https://wordpress.org/?v=6.8.3